Fluidic Analytics Fluidity One-W for antibody affinity and concentration in undiluted serum
The emergence of mutant variants of SARS-CoV-2 and associated concerns about the effects of these mutations on the efficacy of vaccines and therapeutics has underscored the vital importance of understanding the antibody response to SARS-CoV-2.
Using the Fluidity One-W, measurements to determine the affinity, concentration and neutralisation potential of antibodies can be performed directly in human serum. In the recent paper ‘In vitro measurements of protein–protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum’ the capabilities of the Fluidity One-W serum platform were shown.
The product offers an in-solution, receptor-binding competition assay that quantifies the affinity, concentration and neutralisation potential of antibodies against the SARS-CoV-2 spike protein. The platform has the ability to quantitatively profile the underlying protein interactions directly in serum.
Scientists who would like to book a trial, to see how the capabilities of the Fluidity One-W serum can support their research, can do so by contacting ATA Scientific.
For more information: https://www.fluidic.com/resources/antibody-affinity-governs-inhibition-of-SARS-CoV-2/.
Phone: 02 9541 3500
Abcam's knockout (KO) catalogue range and custom service makes it easy for scientists to get...
Developed by Echelon Biosciences, PIP Mass Assays offer researchers a comprehensive selection of...
Protein on Demand allows users to semi-customise the tag and expression system used to produce...